Yuan Ma | Aptamer Drug | Best Researcher Award

Posted on by sciencefather

Dr. Yuan Ma | Aptamer Drug | Best Researcher Award

Dr. Yuan Ma is a Research Assistant Professor at the Hong Kong Baptist University’s School of Chinese Medicine. He holds a PhD in Pharmaceutical Sciences from Peking University, specializing in nucleic acid chemistry and drug delivery systems. His research focuses on aptamer-based translational medicine and drug discovery, with applications in cancer and bone diseases. Dr. Ma has authored over 30 publications in high-impact journals and has been recognized with awards such as the 2024 Young Scientist Award. He combines expertise in organic chemistry, pharmacology, and teaching to advance innovative therapeutic solutions.

Dr. Yuan Ma | Hong Kong Baptist University | China

Profile

SCOPUS ID

ORCID ID

🎓 Education

  • Yuan Ma completed a Bachelor of Science degree in Pharmaceutical Sciences at Peking University in 2013, majoring in Organic Chemistry, Pharmacology, and Pharmaceutical Analysis. He pursued his Master of Science degree at the same institution, focusing on DNA Synthesis, Advanced Medicinal Chemistry, and Tumor Pharmacology, culminating in 2015. In 2019, Yuan earned a Doctor of Philosophy from the Stake Key Laboratory of Natural and Biomimetic Drugs at Peking University, specializing in Nucleic Acid Chemistry, Advanced Organic Chemistry, and Natural Pharmaceutical Chemistry. Her thesis explored novel nucleoside lipid delivery mechanisms.

💼 Experience

  • Dr. Yuan Ma is currently a Research Assistant Professor at the Institute for Advancing Translational Medicine in Bone & Joint Diseases and the School of Chinese Medicine, Hong Kong Baptist University, since 2022. His previous roles include Postdoctoral Research Fellow at the same institution and Associate Research Fellow at Mengchao Hepatobiliary Hospital of Fujian Medical University. He has contributed extensively to translational research in aptamer-based drug discovery and nucleic acid-based diagnostics.

 🏆 Honors and Awards

  • Yuan has received numerous accolades, including the 2024 Young Scientist Award at the 10th International Research Awards on Genetics and Genomics of Diseases in Paris, France. He was also named Peking University Outstanding Graduate in 2019 and received the Peking University Medical Student Special Scholarship in 2017.

🛠️ Skills and Certifications

  • Dr. Yuan possesses a strong command of nucleic acid chemistry, aptamer-based drug discovery, tumor pharmacology, and advanced organic synthesis. He is also proficient in teaching and mentoring, with extensive experience lecturing at undergraduate and postgraduate levels.

🔬 Research Focus

  • Yuan Ma’s research centers on aptamer-based translational research and drug discovery, emphasizing the development of targeted therapies for cancer and bone diseases. He has advanced methodologies in nucleic acid drug development, exploring innovative strategies for improved metabolic stability, binding affinity, and therapeutic efficacy.

Conclusion

  • Dr. Yuan Ma’s work exemplifies the spirit of innovation and dedication necessary for the Best Researcher Award. His contributions to aptamer-based drug discovery and nucleic acid chemistry have not only expanded the scientific understanding of targeted therapies but also paved the way for next-generation treatments in oncology and bone health. Given his academic accomplishments, ongoing research, and the potential for significant medical breakthroughs, He is undoubtedly a leading contender for this prestigious award

📄Publications

  • Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity
    Authors: Zhong, C., Li, N., Wang, S., … Liu, J., Zhang, G.
    Journal: Nature Communications, 2024, 15(1).
  • Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release
    Authors: Ma, Y., Xie, D., Chen, Z., … Lu, A., Zhang, G.
    Journal: Journal of Translational Medicine, 2024, 22(1).
  • Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics
    Authors: Amu, G., Zhang, G., Jing, N., Ma, Y.
    Journal: Journal of Medicinal Chemistry, 2024, 67(21).
  • Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy
    Authors: Ma, Y., Zhang, H., Shen, X., … Tang, T., Zhang, G.
    Journal: Cancer Letters, 2024, 598.
  • Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
    Authors: Xiaohui, T., Wang, L., Yang, X., … Zhang, Z., Zhang, G.
    Journal: Journal of Orthopaedic Translation, 2024, 47.

Jinming Zhou | Medicinal Chemistry | Best Researcher Award

Posted on by sciencefather

Dr. Jinming Zhou | Medicinal Chemistry| Best Researcher Award

Research and Grant Success:

  • Dr. Zhou’s research has been consistently supported by prestigious National Natural Science Foundation (NCSF) grants, with four approvals to date. This grant success not only reflects the high quality and impact of his research but also indicates his capacity to conduct rigorous and relevant studies that address critical health challenges.
Dr. Jinming Zhou, Zhejiang Normal University , China

Profile

Scopus

OrcID

🌱EARLY ACADEMIC PURSUITS

  • Dr. Zhou’s academic journey began at Beijing Normal University, where he earned his Bachelor of Science (B.S.) in 2000 and Master of Science (M.S.) in 2003. His passion for rational drug design led him to pursue a Ph.D. at the Shanghai Institute of Organic Chemistry, where he specialized in this field, establishing a strong foundation in medicinal chemistry. Postdoctoral training followed at McGill University in Canada, where he continued advancing in rational drug design and gained international research exposure.

💼 PROFESSIONAL ENDEAVORS

  • In 2010, Dr. Zhou joined the Institute of Medicinal Biotechnology at the Chinese Academy of Medical Science as an Associate Professor. Demonstrating outstanding contributions in drug research, he achieved full professorship in 2017. His career took a new turn in 2018 when he accepted a professorship at Zhejiang Normal University, where he also became the Director of the Drug Development and Innovation Center. Dr. Zhou’s leadership at this center has been pivotal in establishing innovative practices and groundbreaking projects.

🔬CONTRIBUTIONS AND RESEARCH FOCUS 

  • Dr. Zhou’s research team is at the forefront of developing anti-viral and anti-cancer drugs. His group combines rational drug design and applied medicinal research to create effective therapeutic solutions. His work has a special emphasis on translational medicine, aiming to bridge scientific research and clinical applications. He has secured four prestigious National Natural Science Foundation (NCSF) grants, supporting his work in advancing therapeutic drug development.

📚ACADEMIC CITES 

  • With over a hundred publications, Dr. Zhou has significantly impacted medicinal chemistry, particularly in antiviral and anticancer drug design. His research has become a widely cited reference in related studies, underscoring his scientific contributions’ value and relevance.

🌍IMPACT AND INFLUENCE

  • Dr. Zhou’s influence in the medicinal chemistry field is highlighted by his 100+ publications in high-impact journals, showcasing the scientific community’s recognition of his expertise. His achievements were honored in 2012 with the prestigious “Xiehe Star” award, recognizing his exceptional contributions to the field of drug design.

🌟LEGACY AND FUTURE AND CONTRIBUTIONS

  • As Dr. Zhou continues his work at the Drug Development and Innovation Center, he is shaping a new generation of researchers focused on tackling global health challenges. His legacy is built not only on his published works but also on his mentorship and role in expanding the field of drug innovation. His ongoing research promises to further the understanding of rational drug design and its applications in combating complex diseases.

📄Publications

  • “Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity”
    Authors: Zhang, R., Zheng, Y., Xiang, F., Zhou, J.
    Journal: European Journal of Medicinal Chemistry, 2024, 277, 116756
  • “METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor”
    Authors: Chen, X., Wang, M., Wang, H., Zhou, J., Wu, M.
    Journal: Biomedicine and Pharmacotherapy, 2024, 179, 117366
  • “Autophagy mediated targeting degradation, a promising strategy in drug development”
    Authors: Zhang, J., Pan, X., Ji, W., Zhou, J.
    Journal: Bioorganic Chemistry, 2024, 149, 107466
  • “A novel hydrophobic tag leads to the efficient degradation of programmed death-ligand 1”
    Authors: Gao, J., Xie, Y., Zhang, J., Cen, S., Zhou, J.
    Journal: RSC Medicinal Chemistry, 2024, 15(9), pp. 3038–3047
  • “Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer”
    Authors: Li, C., Han, X., Yan, Q., Wu, M., Zhou, J.
    Journal: Journal of Medicinal Chemistry, 2024, 67(5), pp. 3419–3436

TiePeng Wang | Free Radical Biology and Medicine | Excellence in Innovation

Posted on by sciencefather

Assoc Prof Dr .TiePeng Wang | Free Radical Biology and Medicine | Excellence in Innovation

Extensive Research Experience:
  • Wang has led numerous research projects funded by the National Natural Science Foundation of China and the Science and Technology Program of Xinjiang Production and Construction Corps. His completed and ongoing projects demonstrate his ability to secure funding and contribute to significant scientific advancements.
Assoc prof Dr. TiePeng Wang , Institute of Biophysics, Chinese Academy of Sciences, China

Profile

Scopus

🏛️Early Academic Pursuits

  • Tiepeng Wang earned his BSc in Life Sciences from Jilin University in 2002 and his Ph.D. from the Institute of Biophysics, Chinese Academy of Sciences, in 2007. His early career involved serving as a research assistant and postdoc at the Institute of Biophysics and Neurosciences, where he laid the foundation for his future research in neurodegenerative diseases and redox regulation mechanisms.

👨‍🔬  Professional Endeavors

  • Since 2011, Tiepeng Wang has been an associate professor at Shihezi University’s Medical School and a Special Research Assistant at the Institute of Biophysics since 2021. His career is marked by leading multiple research projects funded by prestigious institutions, including the National Natural Science Foundation of China and the Science and Technology Program of Xinjiang Production and Construction Corps. He has published over 20 research papers and edited several textbooks, significantly contributing to the academic community.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS 

  • Discovery of Necroptosis in Neurodegenerative Diseases: By integrating cellular biology, biochemistry, bioinformatics, and animal behaviorology, Tiepeng Wang discovered that nitric oxide (NO) and necroptosis are the primary pathways leading to neuronal damage in diseases such as Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis. His research indicated that as the severity of these diseases increases, neuronal death pathways shift towards necroptosis.
  • Neuroprotective Effects of GSNOR: His studies identified the enzyme GSNOR as having significant neuroprotective effects against neurotoxicity. He proposed combining creatine with GSNOR to enhance neuroprotection, addressing the limitations of using creatine alone in clinical trials.

📚 ACADEMIC CITES 

  • With a total citation count of 173 for his published papers, Tiepeng Wang’s contributions are widely recognized and referenced in the scientific community. He has edited and co-edited several influential textbooks, including:

    • Advanced Medical Molecular Biology Experimental Techniques (ISBN: 978-7-5192-4603-7)
    • Biochemistry (ISBN: 978-7-5578-6019-6)
    • Basic Research and Clinical Diagnosis of Diabetes (ISBN: 978-7-80756-572-7)
    • Medical Functional Experimentation (ISBN: 978-7-5372-4392-6)
    • Experiment Instruction of Biochemistry and Medical Genetics (ISBN: 978-7-5574-0274-7)
    • Modern Basic Research and Clinical Practice of Diabetes (ISBN: 978-7-5046-6730-4)

🌍 Impact and Influence

  • Tiepeng Wang’s research has had a profound impact on understanding the mechanisms of neuronal damage and developing potential therapeutic strategies for neurodegenerative diseases. His work on NO and necroptosis has opened new avenues for drug development, targeting necroptosis to mitigate neuronal damage.

🤝 Professional Memberships AND Collaborations

    • Young Member, Free Radical Biology and Free Radical Medicine Professional Committee, Chinese Society for Biophysics
    • Member, Chinese Society for Cell Biology
    • Member, Chinese Society for Neuroscience

    Notable Collaborations:

    1. National Key R&D Program of China (2022YFA1303000): Collaboration with Prof. Chen Chang, focusing on maintenance of redox homeostasis and stress intervention.
    2. National Natural Science Foundation of China (81360142): Collaboration with Prof. Xie Jianxin on the impact of obesity on bone metabolism.
    3. National Key Basic Research Program of China (2005CB522804): Collaboration with Prof. Chen Chang on cognitive brain imaging and visual invariance.

    By consistently pushing the frontiers of biomedical research, Tiepeng Wang continues to pave the way for new therapeutic strategies and a deeper understanding of neurodegenerative diseases. His work not only advances scientific knowledge but also holds the promise of improving clinical outcomes for patients worldwide.

🌟 Legacy and Future Contributions

  • Tiepeng Wang’s legacy in the field of biophysics and neuroscience is marked by his significant discoveries and innovative research approaches. His ongoing projects and collaborations, such as the National Key R&D Program of China on redox homeostasis and stress intervention, continue to push the boundaries of our understanding of neuronal health. As a young member of the Free Radical Biology and Free Radical Medicine Professional Committee of the Chinese Society for Biophysics, and as a member of both the Chinese Society for Cell Biology and the Chinese Society for Neuroscience, Tiepeng Wang is poised to make enduring contributions to science and medicine.

📄Publications

  • Optimization of a glutamate excitotoxicity model in cultured cerebellar granule neurons
    • Authors: Wang, T.-P., Zhang, T., Chen, C.
    • Journal: Progress in Biochemistry and Biophysics, 2013, 40(8), pp. 775–782
  • Nitric oxide metabolism controlled by formaldehyde dehydrogenase (fdh, homolog of mammalian GSNOR) plays a crucial role in visual pattern memory in Drosophila
    • Authors: Hou, Q., Jiang, H., Zhang, X., Liu, L., Chen, C.
    • Journal: Nitric Oxide – Biology and Chemistry, 2011, 24(1), pp. 17–24
  • A novel mechanism underlying the susceptibility of neuronal cells to nitric oxide: The occurrence and regulation of protein S-nitrosylation is the checkpoint
    • Authors: He, J., Wang, T., Wang, P., Yin, Q., Chen, C.
    • Journal: Journal of Neurochemistry, 2007, 102(6), pp. 1863–1874
  • Activation of GSNOR transcription by NF-κB negatively regulates NGF-induced PC12 differentiation
    • Authors: Wu, K., Zhang, Y., Wang, P., Wang, T., Chen, C.
    • Journal: Free Radical Research, 2014, 48(9), pp. 1011–1017